FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
16 juin 2020 10h48 HE
|
Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
15 juin 2020 08h19 HE
|
Arch Biopartners
International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Grant of Options
11 juin 2020 08h31 HE
|
Arch Biopartners
TORONTO, June 11, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that its Board of Directors has granted a total of...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
08 juin 2020 07h00 HE
|
Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
19 mai 2020 16h31 HE
|
Arch Biopartners
TORONTO, May 19, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
08 mai 2020 06h00 HE
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation
23 avr. 2020 16h54 HE
|
Arch Biopartners
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model
31 mars 2020 07h36 HE
|
Arch Biopartners
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION
24 mars 2020 07h27 HE
|
Arch Biopartners
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL
17 mars 2020 11h21 HE
|
Arch Biopartners
TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final...